Search

Your search keyword '"Wadlow, Raymond"' showing total 124 results
Start Over Author "Wadlow, Raymond"
124 results on '"Wadlow, Raymond"'

3. Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy

Author

Kabbara, Khaled W., Cannon, Timothy, Winer, Arthur, and Wadlow, Raymond

Subjects
Tumor proteins -- Health aspects -- Analysis, Antineoplastic agents -- Health aspects -- Analysis, Chemotherapy -- Health aspects -- Analysis, Cancer -- Chemotherapy, Antimitotic agents -- Health aspects -- Analysis, Health
Abstract

Cholangiocarcinomas are an aggressive group of heterogeneous malignancies that affect over 210,000 individuals globally each year. Their incidence is rising, particularly in Western countries. Traditionally, cholangiocarcinomas are classified based on anatomic location of the tumor and are treated with similar cytotoxic chemotherapy despite significant molecular and genomic differences. With the rise of genetic and molecular sequencing, several driver mutations have been identified and targeted as novel therapeutic approaches. The most common genomic alterations include changes in FGFR2, IDH1, KRAS, BRAF, HER2, and the tumor suppressor p53. In addition, increased understanding of the cellular and molecular constituents of the tumor microenvironment (TME) has created opportunities for further novel therapeutic approaches. New strategies using combination therapies targeting driver mutations and various components of the TME hold promise for improved patient outcomes. This review covers the evolving molecular and therapeutic landscape of cholangiocarcinoma., Introduction Cholangiocarcinomas (CCAs) comprise a rare and aggressive group of heterogeneous malignancies that combined with gallbladder cancers affect more than 210,000 individuals globally on an annual basis. (1) Well-characterized risk [...]

Published
2022

5. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals

Author

Zogopoulos, George, primary, Haimi, Ido, additional, Sanoba, Shenin A., additional, Everett, Jessica N., additional, Wang, Yifan, additional, Katona, Bryson W., additional, Farrell, James J., additional, Grossberg, Aaron J., additional, Paiella, Salvatore, additional, Klute, Kelsey A., additional, Bi, Yan, additional, Wallace, Michael B., additional, Kwon, Richard S., additional, Stoffel, Elena M., additional, Wadlow, Raymond C., additional, Sussman, Daniel A., additional, Merchant, Nipun B., additional, Permuth, Jennifer B., additional, Golan, Talia, additional, Raitses-Gurevich, Maria, additional, Lowy, Andrew M., additional, Liau, Joy, additional, Jeter, Joanne M., additional, Lindberg, James M., additional, Chung, Daniel C., additional, Earl, Julie, additional, Brentnall, Teresa A., additional, Schrader, Kasmintan A., additional, Kaul, Vivek, additional, Huang, Chenchan, additional, Chandarana, Hersh, additional, Smerdon, Caroline, additional, Graff, John J., additional, Kastrinos, Fay, additional, Kupfer, Sonia S., additional, Lucas, Aimee L., additional, Sears, Rosalie C., additional, Brand, Randall E., additional, Parmigiani, Giovanni, additional, Simeone, Diane M., additional, and _, _, additional

Published
2024
Full Text
View/download PDF

6. The impact of Wnt pathway alterations including RNF43, GNAS, CTNNB1, and APC on prognosis and potential therapeutic vulnerability in pancreatic adenocarcinoma (PDAC).

Author

Takebe, Naoko, primary, Blais, Edik Matthew, additional, Huynh, Jasmine, additional, Thach, Dzung, additional, de Arbeloa, Patricia Miren, additional, Matrisian, Lynn McCormick, additional, Petricoin, Emanuel, additional, Pishvaian, Michael J., additional, Chung, Vincent, additional, Boland, Patrick M, additional, Yaeger, Rona, additional, Wadlow, Raymond Couric, additional, Hendifar, Andrew Eugene, additional, Nevler, Avinoam, additional, and Cannon, Timothy Lewis, additional

Published
2024
Full Text
View/download PDF

7. Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

Author

Rojas, Carlos, primary, Ryoo, Baek-Yeol, additional, Rha, Sun Young, additional, Kelley, Robin Kate, additional, Hubert, Ayala, additional, Painemal, Claudio, additional, Wadlow, Raymond Couric, additional, Gong, Jun, additional, Fan, Li, additional, Jin, Fan, additional, Naik, Girish S., additional, and Macarulla, Teresa, additional

Published
2024
Full Text
View/download PDF

9. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

Author

Goyal, Lipika, Chaudhary, Surendra Pal, Kwak, Eunice L., Abrams, Thomas A., Carpenter, Amanda N., Wolpin, Brian M., Wadlow, Raymond C., Allen, Jill N., Heist, Rebecca, McCleary, Nadine Jackson, Chan, Jennifer A., Goessling, Wolfram, Schrag, Deborah, Ng, Kimmie, Enzinger, Peter C., Ryan, David P., and Clark, Jeffrey W.

Published
2020
Full Text
View/download PDF

10. Supplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance

Author

Katona, Bryson W., primary, Klute, Kelsey, primary, Brand, Randall E., primary, Everett, Jessica N., primary, Farrell, James J., primary, Hawthorne, Kieran, primary, Kaul, Vivek, primary, Kupfer, Sonia S., primary, Paiella, Salvatore, primary, Simeone, Diane M., primary, Sussman, Daniel A., primary, Zogopoulos, George, primary, Lucas, Aimee L., primary, Kastrinos, Fay, primary, Bi, Yan, primary, Brentnall, Teresa, primary, Chung, Daniel, primary, Earl, Julie, primary, Gaddam, Srinivas, primary, Gallinger, Steve, primary, Graff, John J., primary, Greenhalf, William, primary, Grossberg, Aaron, primary, Hart, Philip, primary, Idos, Gregory, primary, Jeter, Joanne, primary, Lindberg, James, primary, Lowy, Andrew, primary, Permuth, Jennifer, primary, Raitses-Gurevich, Maria, primary, Schrader, Intan, primary, Siveke, Jens, primary, Stoffel, Elena, primary, Vornhuelz, Marlies, primary, and Wadlow, Raymond, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance

Author

Katona, Bryson W., primary, Klute, Kelsey, primary, Brand, Randall E., primary, Everett, Jessica N., primary, Farrell, James J., primary, Hawthorne, Kieran, primary, Kaul, Vivek, primary, Kupfer, Sonia S., primary, Paiella, Salvatore, primary, Simeone, Diane M., primary, Sussman, Daniel A., primary, Zogopoulos, George, primary, Lucas, Aimee L., primary, Kastrinos, Fay, primary, Bi, Yan, primary, Brentnall, Teresa, primary, Chung, Daniel, primary, Earl, Julie, primary, Gaddam, Srinivas, primary, Gallinger, Steve, primary, Graff, John J., primary, Greenhalf, William, primary, Grossberg, Aaron, primary, Hart, Philip, primary, Idos, Gregory, primary, Jeter, Joanne, primary, Lindberg, James, primary, Lowy, Andrew, primary, Permuth, Jennifer, primary, Raitses-Gurevich, Maria, primary, Schrader, Intan, primary, Siveke, Jens, primary, Stoffel, Elena, primary, Vornhuelz, Marlies, primary, and Wadlow, Raymond, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance

Author

Katona, Bryson W., primary, Klute, Kelsey, primary, Brand, Randall E., primary, Everett, Jessica N., primary, Farrell, James J., primary, Hawthorne, Kieran, primary, Kaul, Vivek, primary, Kupfer, Sonia S., primary, Paiella, Salvatore, primary, Simeone, Diane M., primary, Sussman, Daniel A., primary, Zogopoulos, George, primary, Lucas, Aimee L., primary, Kastrinos, Fay, primary, Bi, Yan, primary, Brentnall, Teresa, primary, Chung, Daniel, primary, Earl, Julie, primary, Gaddam, Srinivas, primary, Gallinger, Steve, primary, Graff, John J., primary, Greenhalf, William, primary, Grossberg, Aaron, primary, Hart, Philip, primary, Idos, Gregory, primary, Jeter, Joanne, primary, Lindberg, James, primary, Lowy, Andrew, primary, Permuth, Jennifer, primary, Raitses-Gurevich, Maria, primary, Schrader, Intan, primary, Siveke, Jens, primary, Stoffel, Elena, primary, Vornhuelz, Marlies, primary, and Wadlow, Raymond, primary

Published
2023
Full Text
View/download PDF

13. Data from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance

Author

Katona, Bryson W., primary, Klute, Kelsey, primary, Brand, Randall E., primary, Everett, Jessica N., primary, Farrell, James J., primary, Hawthorne, Kieran, primary, Kaul, Vivek, primary, Kupfer, Sonia S., primary, Paiella, Salvatore, primary, Simeone, Diane M., primary, Sussman, Daniel A., primary, Zogopoulos, George, primary, Lucas, Aimee L., primary, Kastrinos, Fay, primary, Bi, Yan, primary, Brentnall, Teresa, primary, Chung, Daniel, primary, Earl, Julie, primary, Gaddam, Srinivas, primary, Gallinger, Steve, primary, Graff, John J., primary, Greenhalf, William, primary, Grossberg, Aaron, primary, Hart, Philip, primary, Idos, Gregory, primary, Jeter, Joanne, primary, Lindberg, James, primary, Lowy, Andrew, primary, Permuth, Jennifer, primary, Raitses-Gurevich, Maria, primary, Schrader, Intan, primary, Siveke, Jens, primary, Stoffel, Elena, primary, Vornhuelz, Marlies, primary, and Wadlow, Raymond, primary

Published
2023
Full Text
View/download PDF

14. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Author

Adoo, Clarence, Anderson, Thomas, Asselah, Jamil, Azambuja, Alan, Bampton, Carolyn, Barrios, Carlos Henrique, Bekaii-Saab, Tanios, Bohuslav, Melichar, Chang, David, Chen, Jen-Shi, Chen, Yeu-Chin, Choi, Hye Jin, Chung, Ik Joo, Chung, Vincent, Csoszi, Tibor, Cubillo, Antonio, DeMarco, Linda, de Wit, Maike, Dragovich, Tomislav, Edenfield, William, Fein, Luis Enrique, Franke, Fábio, Fuchs, Martin, Gonzales-Cruz, Vega, Gozza, Alberto, Fernando, Rivera Herrero, Iaffaioli, Rosario, Jakesova, Jitka, Kahan, Zsuzsanna, Karimi, Misagh, Kim, Jun Suk, Korbenfeld, Ernesto, Lang, Istvan, Lee, Fa-Chyi, Lee, Kuan-Der, Lipton, Lara, Ma, Wen Wee, Mangel, Laszlo, Mena, Raul, Palmer, Daniel, Pant, Shubham, Park, Joon Oh, Piacentini, Paolo, Pelzer, Uwe, Plazas, Javier Gallego, Prasad, Cooray, Rau, Kun-Ming, Raoul, Jean-Luc, Richards, Donald, Ross, Paul, Schlittler, Luis, Smakal, Martin, Stahalova, Vladimira, Sternberg, Cora, Seufferlein, Thomas, Tebbutt, Niall, Vinholes, Jeferson Jose, Wadlow, Raymond, Wenczl, Milkos, Wong, Mark, Wang-Gillam, Andrea, Li, Chung-Pin, Bodoky, György, Dean, Andrew, Shan, Yan-Shen, Jameson, Gayle, Macarulla, Teresa, Lee, Kyung-Hun, Cunningham, David, Blanc, Jean F, Hubner, Richard A, Chiu, Chang-Fang, Schwartsmann, Gilberto, Siveke, Jens T, Braiteh, Fadi, Moyo, Victor, Belanger, Bruce, Dhindsa, Navreet, Bayever, Eliel, Von Hoff, Daniel D, and Chen, Li-Tzong

Published
2016
Full Text
View/download PDF

16. A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma

Author

Hong, Theodore S., Ryan, David P., Borger, Darrell R., Blaszkowsky, Lawrence S., Yeap, Beow Y., Ancukiewicz, Marek, Deshpande, Vikram, Shinagare, Shweta, Wo, Jennifer Y., Boucher, Yves, Wadlow, Raymond C., Kwak, Eunice L., Allen, Jill N., Clark, Jeffrey W., Zhu, Andrew X., Ferrone, Cristina R., Mamon, Harvey J., Adams, Judith, Winrich, Barbara, Grillo, Tarin, Jain, Rakesh K., DeLaney, Thomas F., Fernandez-del Castillo, Carlos, and Duda, Dan G.

Published
2014
Full Text
View/download PDF

17. Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer

Author

Al-Hajeili, Marwan, Shields, Anthony F., Hwang, Jimmy J., Wadlow, Raymond C., and Marshall, John L.

Subjects
Colorectal cancer -- Diagnosis -- Genetic aspects -- Health aspects -- Care and treatment, Molecular diagnostic techniques -- Innovations, Precision medicine -- Innovations, Biological markers -- Identification and classification, Toxicity, Tumors, Physicians, Health
Abstract

Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient. Proper utilization of these biomarkers can enable physicians to tailor therapeutic strategies to maximize the likelihood of response and minimize treatment toxicity. In the management of colorectal cancer, tremendous progress has been made in the development of strategies for immune checkpoint inhibition; in refinement of agents and approaches used in targeted therapy; and in techniques for molecular subtyping of tumor samples that have identified patient subgroups with clinically relevant cellular differences potentially affecting clinical management and treatment outcome. In this article, we discuss several of the commonly tested markers in colorectal cancer--including microsatellite instability, RAS/RAF, DPD, HER2, UTG1A1, TS, and Immunoscore--and highlight their prevalence, prognostic and predictive value, and current role in the overall treatment paradigm., Introduction Colorectal cancer is the fourth most common cancer diagnosed in the United States and the second leading cause of cancer-related death. Approximately 140,000 cases are diagnosed annually in the [...]

Published
2017

22. Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC).

Author

Osipov, Arsen, primary, Blais, Edik Matthew, additional, Davelaar, John, additional, Moshayedi, Natalie, additional, Nikravesh, Nima, additional, Gresham, Gillian, additional, Zheng, Lei, additional, McRee, Autumn Jackson, additional, Chuy, Jennifer W., additional, Shroff, Rachna T., additional, Wadlow, Raymond Couric, additional, Gregory, Gary Lee, additional, DeArbeloa, Patricia, additional, Matrisian, Lynn McCormick, additional, Petricoin, Emanuel, additional, Pishvaian, Michael J., additional, Thomassian, Shant, additional, Gong, Jun, additional, and Hendifar, Andrew Eugene, additional

Published
2022
Full Text
View/download PDF

23. Association of pancreatic adenocarcinoma location (head/body/tail) with DDR mutation status and response to platinum-based therapy.

Author

Micaily, Ida, primary, Blais, Edik Matthew, additional, Cohen, Steven J, additional, Cannaday, Shawnna, additional, Krampitz, Geoffrey, additional, Wadlow, Raymond Couric, additional, Shroff, Rachna T., additional, McRee, Autumn Jackson, additional, Chuy, Jennifer W., additional, Zheng, Lei, additional, Hendifar, Andrew Eugene, additional, Matrisian, Lynn McCormick, additional, Gregory, Gary Lee, additional, Thach, Dzung, additional, Brody, Jonathan Robert, additional, Petricoin, Emanuel, additional, Pishvaian, Michael J., additional, Lavu, Harish, additional, Yeo, Charles, additional, and Basu Mallick, Atrayee, additional

Published
2022
Full Text
View/download PDF

24. Early palliative care involvement in gastrointestinal malignancies: A community cancer center perspective.

Author

Hwang, Min Woo, Curtis-Romonchuk, Shairna, Dvergsten, Erik, Pierattini, Chiara, Karovic, Sanja, and Wadlow, Raymond Couric

Abstract

198 Background: Early involvement of palliative care (PC) specialists enhances quality of life for patients with advanced gastrointestinal (GI) cancer. Methods: This retrospective study evaluated patients with newly diagnosed stage III and IV GI cancer seen at a large community cancer center between 10/1/22 and 9/30/23. We compared patients seen by a PC provider in clinic at least once to those without an outpatient PC visit within the one-year study period. Results: 283 patients with stage III/IV colorectal (42%), gastroesophageal (23%), pancreatic (16%), hepatobiliary (12%), and other GI cancers (8%) received care within the study period (Table). Of these, 49 (17%) had at least one PC clinic visit, and 234 (83%) had no PC visits. Patients with pancreatic (35% vs 12%) and hepatobiliary cancer (20% vs 10%) were over-represented in the group receiving PC vs those without PC, while patients with colorectal cancer were under-represented (20% vs 47%). Greater percentages of patients in the group receiving PC completed advanced care planning (ACP) documents (63% vs 24%) and died during the study period (65% vs 15%). Conclusions: A minority of patients with GI malignancies at a large community cancer center are seen by an outpatient PC provider during the first year after diagnosis. These patients are more likely to have tumor types associated with worse prognosis, to complete ACPs, and to die within one year. Broader delivery of early PC will require expanded services in community cancer centers and continued development of tools for identifying patients most likely to benefit. The distribution of gastrointestinal cancer between outpatient palliative care visit and no outpatient palliative care visit. Primary cancer PC No PC Total Colorectal 10 (20% | 8%) 110 (47% | 92%) 120 (42% | 100%) Gastroesophageal 10 (20% | 16%) 54 (23% | 84%) 64 (23% | 100%) Pancreatic 17 (35% | 39%) 27 (12% | 61%) 44 (16% | 100%) Hepatobiliary 10 (20% | 30%) 23 (10% | 70%) 33 (12% | 100%) Other GI 2 (4% | 9%) 20 (9% | 91%) 22 (8% | 100%) Total 49 (100% | 17%) 234 (100% | 83%) 283 (100% | 100%) PC: Palliative care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. MP82-09 PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY

Author

Petrylak, Daniel, Vogelzang, Nicholas, Chatta, Kamal, Fleming, Mark, Smith, David, Appleman, Leonard, Hussain, Arif, Modiano, Manuel, Singh, Parminder, Tagawa, Scott, Gore, Ira, McClay, Ed, Mega, Anthony, Sartor, Oliver, Somer, Brad, Wadlow, Raymond, Shore, Neal, Stambler, Nancy, DiPippo, Vincent, and Israel, Robert

Published
2015
Full Text
View/download PDF

26. Concurrent BRAFV600E and BRCA mutations in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Prevalence and case series of mCRC (pts) with prolonged overall survival (OS).

Author

Cannon, Timothy Lewis, primary, Randall, Jamie, additional, Sokol, Ethan, additional, Alexander, Sonja, additional, Wadlow, Raymond Couric, additional, Barnett, Daniel, additional, Rayes, Danny, additional, Deeken, John F., additional, Nimeiri, Halla, additional, and McGregor, Kimberly, additional

Published
2021
Full Text
View/download PDF

31. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma

Author

Roth, Marc T., primary, Cardin, Dana Backlund, additional, Borazanci, Erkut Hasan, additional, Steinbach, Margaux, additional, Picozzi, Vincent J., additional, Rosemury, Alexander, additional, Wadlow, Raymond Couric, additional, Newman, Robert A., additional, and Berlin, Jordan, additional

Published
2020
Full Text
View/download PDF

34. PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study

Author

Petrylak, Daniel P., primary, Vogelzang, Nicholas J., additional, Chatta, Kamal, additional, Fleming, Mark T., additional, Smith, David C., additional, Appleman, Leonard J., additional, Hussain, Arif, additional, Modiano, Manuel, additional, Singh, Parminder, additional, Tagawa, Scott T., additional, Gore, Ira, additional, McClay, Edward F., additional, Mega, Anthony E., additional, Sartor, A. Oliver, additional, Somer, Bradley, additional, Wadlow, Raymond, additional, Shore, Neal D., additional, Olson, William C., additional, Stambler, Nancy, additional, DiPippo, Vincent A., additional, and Israel, Robert J., additional

Published
2019
Full Text
View/download PDF

35. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Author

Barbie, David A., Tamayo, Pablo, Boehm, Jesse S., Kim, So Young, Moody, Susan E., Dunn, Ian F., Schinzel, Anna C., Sandy, Peter, Meylan, Etienne, Scholl, Claudia, Fröhling, Stefan, Chan, Edmond M., Sos, Martin L., Michel, Kathrin, Mermel, Craig, Silver, Serena J., Weir, Barbara A., Reiling, Jan H., Sheng, Qing, Gupta, Piyush B., Wadlow, Raymond C., Le, Hanh, Hoersch, Sebastian, Wittner, Ben S., Ramaswamy, Sridhar, Livingston, David M., Sabatini, David M., Meyerson, Matthew, Thomas, Roman K., Lander, Eric S., Mesirov, Jill P., Root, David E., Gilliland, Gary D., Jacks, Tyler, and Hahn, William C.

Published
2009
Full Text
View/download PDF

37. Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study.

Author

Salgia, Nicholas, primary, Pal, Sumanta K., additional, Chung, Vincent, additional, Tagawa, Scott T., additional, Picus, Joel, additional, Babiker, Hani M., additional, Gupta, Sumati, additional, Wadlow, Raymond Couric, additional, Poore, Julie, additional, Peterson, Christine, additional, and Benaim, Ely, additional

Published
2019
Full Text
View/download PDF

39. PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study.

Author

Petrylak, Daniel P., Vogelzang, Nicholas J., Chatta, Kamal, Fleming, Mark T., Smith, David C., Appleman, Leonard J., Hussain, Arif, Modiano, Manuel, Singh, Parminder, Tagawa, Scott T., Gore, Ira, McClay, Edward F., Mega, Anthony E., Sartor, A. Oliver, Somer, Bradley, Wadlow, Raymond, Shore, Neal D., Olson, William C., Stambler, Nancy, and DiPippo, Vincent A.

Published
2020
Full Text
View/download PDF

40. Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).

Author

Adashek, Jacob, primary, Pal, Sumanta K., additional, Chung, Vincent M., additional, Tagawa, Scott T., additional, Picus, Joel, additional, Babiker, Hani M., additional, Gupta, Sumati, additional, Wadlow, Raymond Couric, additional, Poore, Julie, additional, Peterson, Christine, additional, and Benaim, Ely, additional

Published
2018
Full Text
View/download PDF

42. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Author

Wang-Gillam, Andrea, primary, Li, Chung-Pin, additional, Bodoky, György, additional, Dean, Andrew, additional, Shan, Yan-Shen, additional, Jameson, Gayle, additional, Macarulla, Teresa, additional, Lee, Kyung-Hun, additional, Cunningham, David, additional, Blanc, Jean F, additional, Hubner, Richard A, additional, Chiu, Chang-Fang, additional, Schwartsmann, Gilberto, additional, Siveke, Jens T, additional, Braiteh, Fadi, additional, Moyo, Victor, additional, Belanger, Bruce, additional, Dhindsa, Navreet, additional, Bayever, Eliel, additional, Von Hoff, Daniel D, additional, Chen, Li-Tzong, additional, Adoo, Clarence, additional, Anderson, Thomas, additional, Asselah, Jamil, additional, Azambuja, Alan, additional, Bampton, Carolyn, additional, Barrios, Carlos Henrique, additional, Bekaii-Saab, Tanios, additional, Bohuslav, Melichar, additional, Chang, David, additional, Chen, Jen-Shi, additional, Chen, Yeu-Chin, additional, Choi, Hye Jin, additional, Chung, Ik Joo, additional, Chung, Vincent, additional, Csoszi, Tibor, additional, Cubillo, Antonio, additional, DeMarco, Linda, additional, de Wit, Maike, additional, Dragovich, Tomislav, additional, Edenfield, William, additional, Fein, Luis Enrique, additional, Franke, Fábio, additional, Fuchs, Martin, additional, Gonzales-Cruz, Vega, additional, Gozza, Alberto, additional, Fernando, Rivera Herrero, additional, Iaffaioli, Rosario, additional, Jakesova, Jitka, additional, Kahan, Zsuzsanna, additional, Karimi, Misagh, additional, Kim, Jun Suk, additional, Korbenfeld, Ernesto, additional, Lang, Istvan, additional, Lee, Fa-Chyi, additional, Lee, Kuan-Der, additional, Lipton, Lara, additional, Ma, Wen Wee, additional, Mangel, Laszlo, additional, Mena, Raul, additional, Palmer, Daniel, additional, Pant, Shubham, additional, Park, Joon Oh, additional, Piacentini, Paolo, additional, Pelzer, Uwe, additional, Plazas, Javier Gallego, additional, Prasad, Cooray, additional, Rau, Kun-Ming, additional, Raoul, Jean-Luc, additional, Richards, Donald, additional, Ross, Paul, additional, Schlittler, Luis, additional, Smakal, Martin, additional, Stahalova, Vladimira, additional, Sternberg, Cora, additional, Seufferlein, Thomas, additional, Tebbutt, Niall, additional, Vinholes, Jeferson Jose, additional, Wadlow, Raymond, additional, Wenczl, Milkos, additional, and Wong, Mark, additional

Published
2016
Full Text
View/download PDF

43. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Author

Koch Institute for Integrative Cancer Research at MIT, Sandy, Peter, Jacks, Tyler E., Scholl, Claudia, Frohling, Stefan, Dunn, Ian F., Schinzel, Anna C., Barbie, David A., Kim, So Young, Silver, Serena J., Tamayo, Pablo, Wadlow, Raymond C., Ramaswamy, Sridhar, Dohner, Konstanze, Bullinger, Lars, Boehm, Jesse S., Root, David E., Hahn, William C., Gilliland, D. Gary, Jacks, Tyler E, Koch Institute for Integrative Cancer Research at MIT, Sandy, Peter, Jacks, Tyler E., Scholl, Claudia, Frohling, Stefan, Dunn, Ian F., Schinzel, Anna C., Barbie, David A., Kim, So Young, Silver, Serena J., Tamayo, Pablo, Wadlow, Raymond C., Ramaswamy, Sridhar, Dohner, Konstanze, Bullinger, Lars, Boehm, Jesse S., Root, David E., Hahn, William C., Gilliland, D. Gary, and Jacks, Tyler E

Abstract

An alternative to therapeutic targeting of oncogenes is to perform “synthetic lethality” screens for genes that are essential only in the context of specific cancer-causing mutations. We used high-throughput RNA interference (RNAi) to identify synthetic lethal interactions in cancer cells harboring mutant KRAS, the most commonly mutated human oncogene. We find that cells that are dependent on mutant KRAS exhibit sensitivity to suppression of the serine/threonine kinase STK33 irrespective of tissue origin, whereas STK33 is not required by KRAS-independent cells. STK33 promotes cancer cell viability in a kinase activity-dependent manner by regulating the suppression of mitochondrial apoptosis mediated through S6K1-induced inactivation of the death agonist BAD selectively in mutant KRAS-dependent cells. These observations identify STK33 as a target for treatment of mutant KRAS-driven cancers and demonstrate the potential of RNAi screens for discovering functional dependencies created by oncogenic mutations that may enable therapeutic intervention for cancers with “undruggable” genetic alterations., National Institutes of Health (U.S.) (grant R33 CA128625), National Institutes of Health (U.S.) (grant NIH U54 CA112962), National Institutes of Health (U.S.) (grant P01 CA095616), National Institutes of Health (U.S.) (grant P01 CA66996), Starr Cancer Consortium, Doris Duke Charitable Foundation, MPN Research Foundation, Deutsche Forschungsgemeinschaft (grant SCHO 1215/1-1), Deutsche Forschungsgemeinschaft (grant FR 2113/1-1), Brain Science Foundation, Leukemia & Lymphoma Society of America

Published
2015

46. A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

Author

Petrylak, Daniel Peter, primary, Vogelzang, Nicholas J., additional, Chatta, Gurkamal S., additional, Fleming, Mark T., additional, Smith, David C., additional, Appleman, Leonard Joseph, additional, Hussain, Arif, additional, Modiano, Manuel, additional, Singh, Parminder, additional, Tagawa, Scott T., additional, Gore, Ira, additional, McClay, Edward Francis, additional, Mega, Anthony E., additional, Sartor, A. Oliver, additional, Somer, Bradley G., additional, Wadlow, Raymond Couric, additional, Shore, Neal D., additional, Stambler, Nancy, additional, DiPippo, Vincent A., additional, and Israel, Robert Joseph, additional

Published
2015
Full Text
View/download PDF

48. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Author

Barbie, David, Tamayo, Pablo, Boehm, Jesse, Kim, So Young, Moody, Susan, Dunn, Ian, Schinzel, Anna C., Sandy, Peter, Meylan, Etienne, Scholl, Claudia, Fröhling, Stefan, Chan, Edmond M., Sos, Martin L., Michel, Kathrin, Mermel, Craig, Silver, Serena J., Weir, Barbara, Reiling, Jan, Sheng, Qing, Gupta, Piyush B, Wadlow, Raymond, Le, Hanh, Hoersch, Sebastian, Wittner, Ben, Ramaswamy, Sridhar, Livingston, David, Sabatini, David, Meyerson, Matthew, Thomas, Roman K., Lander, Eric, Mesirov, Jill, Root, David, Gilliland, Dwight Gary, Jacks, Tyler, Hahne, William, Barbie, David, Tamayo, Pablo, Boehm, Jesse, Kim, So Young, Moody, Susan, Dunn, Ian, Schinzel, Anna C., Sandy, Peter, Meylan, Etienne, Scholl, Claudia, Fröhling, Stefan, Chan, Edmond M., Sos, Martin L., Michel, Kathrin, Mermel, Craig, Silver, Serena J., Weir, Barbara, Reiling, Jan, Sheng, Qing, Gupta, Piyush B, Wadlow, Raymond, Le, Hanh, Hoersch, Sebastian, Wittner, Ben, Ramaswamy, Sridhar, Livingston, David, Sabatini, David, Meyerson, Matthew, Thomas, Roman K., Lander, Eric, Mesirov, Jill, Root, David, Gilliland, Dwight Gary, Jacks, Tyler, and Hahne, William

Abstract

info:eu-repo/semantics/published

Published
2009

49. A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.

Author

Kwak, Eunice Lee, primary, Goyal, Lipika, additional, Abrams, Thomas Adam, additional, Carpenter, Amanda, additional, Wolpin, Brian M., additional, Wadlow, Raymond Couric, additional, Allen, Jill N., additional, Heist, Rebecca Suk, additional, McCleary, Nadine Jackson, additional, Chan, Jennifer A., additional, Goessling, Wolfram, additional, Schrag, Deborah, additional, Evans, Colleen, additional, Ng, Kimmie, additional, Enzinger, Peter C., additional, and Ryan, David P., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results